Deficiency of Adenosine Deaminase 2 (DADA 2)
ACR on Air
Navigating Insurance Approvals for TNF Inhibitors
This chapter explores the hurdles related to insurance approvals for TNF inhibitors without formal FDA approval for specific uses. It emphasizes the importance of clinician consensus in advocating for these treatments and the strides made in improving the approval process for affected patients.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
